

Third meeting on  
**T-cell and NK-cell based immunotherapies for Lymphoid Malignancies**  
Bologna, Royal Hotel, September 13-14, 2024

**PROGRAM**

**First DAY**

08:45 am Welcome and introduction

**SESSION I – The evolving role of checkpoint inhibitors in lymphomas**

09:00 am In first line Hodgkin lymphoma  
09:20 am The setting of R/R Hodgkin lymphoma  
09:40 am Aggressive non-Hodgkin lymphoma  
10:00 am Novel checkpoint inhibitors  
10:20 am How to overcome resistance to checkpoints

*10:40 am Coffee break*

**SESSION II – Bispecific T-cell engagers in lymphoma and myeloma**

11:00 am Overview aggressive NHL  
11:20 am Overview indolent NHL  
11:40 am Resistance and combinations to bispecifics in NHL

**Round table:**

12:20 pm Overview in multiple myeloma  
12:40 pm Resistance and combinations of bispecifics

**Round table:**

*01:20 pm Lunch*

**SESSION III – Lymphoma: clinical updates in CAR-T therapies**

02:20 pm CAR-T for DLBCL: real-world data in third line  
02:40 pm CAR-T for DLBCL: from second-line clinical trials to RWD  
03:00 pm First line CAR-T: ZUMA 12 and beyond  
03:20 pm CAR-T for follicular lymphoma and real-world data  
03:40 pm CAR-T for mantle cell lymphoma  
04:00 pm CAR-T for T-cell lymphomas  
04:20 pm Targeting Hodgkin lymphoma with T and  
NK-cell based immunotherapies

**SESSION IV – CAR-T resistance and next-generation CAR-T therapies for NHL**

- 04:40 pm Mechanisms of resistance: clinical evidence
- 05:00 pm Mechanisms of resistance: laboratory evidence
- 05:20 pm The role of lymphodepletion
- 05:40 pm CAR-T and microbiome
- 06:00 pm Overcoming CAR-T toxicities

## Second DAY

### SESSION V – Innovative immunotherapy research “MADE IN ITALY”

- 08:30 am Roma, Hospital Bambin Gesù'
- 08:40 am Monza, IRCCS San Gerardo
- 08:50 am Milano, San Raffaele Hospital
- 09:00 am Milano, Istituto Nazionale dei Tumori
- 09:10 am Bologna, Istituto Seragnoli
- 09:20 am. Perugia, Ospedale Santa Maria della Misericordia
- 09:30 am Padova, Istituto Oncologico Veneto - IRCCS

### SESSION VI – Novel immunotherapies for lymphoid malignancies

- 09:40 am Allo CAR-T cells
- 10:00 am NK biAbs and NK CAR-T cells
- 10:20 am Gamma delta CAR-T20 cells
- 10:40 am Novel CAR-T and CAR-T combinations for NHL
- 11:00 am Gene-editing to enhance CAR-T immunotherapies

*11:20 am Coffee break*

### SESSION VII – CAR-T cell immunotherapy for multiple myeloma

- 11:40 am Clinical results in late lines
- 12:00 pm Clinical results in early lines
- 12:20 pm Clinical resistance
- 12:40 pm Laboratory resistance
- 01:00 pm Novel CAR-T and combinations

*01:20 pm Lunch*

### SESSION VIII – Hot debates in immunotherapy for lymphomas

- 02:20 pm Bispecific vs CAR-T in MM
- 02:40 pm Bispecific vs CAR-T in DLBCL and FL
- 03:00 pm Auto vs allo CAR-T
- 03:20 pm Conclusions and arrivederci!